Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19
Related Articles
Gilead Sciences, Inc.
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Partnerships and Community | Gilead
Learn more about our partnerships with community organizations to help address health challenges and barriers to care around the world.
FDA Expands Indication for Gilead’s Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
FDA Expands Indication for Gilead’s Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences Announces Completion of Acquisition of CymaBay
Unilever to Cut 7,500 Jobs and Spin Off Ben & Jerry’s Ice Cream Unit
The consumer goods giant said the moves would make for a “simpler, more focused company” as consumers trade down to cheaper brands amid high inflation.
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19